SE0201713D0 - New methods and use III - Google Patents

New methods and use III

Info

Publication number
SE0201713D0
SE0201713D0 SE0201713A SE0201713A SE0201713D0 SE 0201713 D0 SE0201713 D0 SE 0201713D0 SE 0201713 A SE0201713 A SE 0201713A SE 0201713 A SE0201713 A SE 0201713A SE 0201713 D0 SE0201713 D0 SE 0201713D0
Authority
SE
Sweden
Prior art keywords
glutamate
vertebrate
bird
including mammal
new methods
Prior art date
Application number
SE0201713A
Other languages
English (en)
Inventor
Tadeusz Studzinski
Piedra Jose Luis Valverde
Stefan G Pierzynowski
Original Assignee
Gramineer Internat Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27354772&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE0201713(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE0104385A external-priority patent/SE520842C2/sv
Application filed by Gramineer Internat Ab filed Critical Gramineer Internat Ab
Priority to SE0201713A priority Critical patent/SE0201713D0/sv
Publication of SE0201713D0 publication Critical patent/SE0201713D0/sv
Priority to MXPA04004904A priority patent/MXPA04004904A/es
Priority to AU2002366111A priority patent/AU2002366111B2/en
Priority to BR0214364-0A priority patent/BR0214364A/pt
Priority to KR1020047007846A priority patent/KR100961291B1/ko
Priority to CNB028245253A priority patent/CN100531731C/zh
Priority to US10/496,350 priority patent/US8603981B2/en
Priority to EP02791128.8A priority patent/EP1446112B1/en
Priority to DK02791128.8T priority patent/DK1446112T3/da
Priority to CA2467676A priority patent/CA2467676C/en
Priority to ES02791128T priority patent/ES2431085T3/es
Priority to PT2791128T priority patent/PT1446112E/pt
Priority to PCT/SE2002/002123 priority patent/WO2003043626A1/en
Priority to JP2003545307A priority patent/JP4447913B2/ja
Priority to HK05101425.8A priority patent/HK1071059A1/xx
Priority to US14/101,234 priority patent/US9233088B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
SE0201713A 2001-11-23 2002-06-06 New methods and use III SE0201713D0 (sv)

Priority Applications (16)

Application Number Priority Date Filing Date Title
SE0201713A SE0201713D0 (sv) 2001-11-23 2002-06-06 New methods and use III
PT2791128T PT1446112E (pt) 2001-11-23 2002-11-22 Utilização de glutamato, derivados ou metabolitos de glutamato, análogos de glutamato ou misturas dos mesmos para o fabrico de uma composição para o tratamento da osteoporose
PCT/SE2002/002123 WO2003043626A1 (en) 2001-11-23 2002-11-22 Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis
JP2003545307A JP4447913B2 (ja) 2001-11-23 2002-11-22 オステオポローシス治療のための組成物の製造のためのグルタミン酸塩、グルタミン酸塩誘導体又はグルタミン酸塩代謝物、グルタミン酸塩アナログ或いはそれらの混合物の使用
US10/496,350 US8603981B2 (en) 2001-11-23 2002-11-22 Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis
DK02791128.8T DK1446112T3 (da) 2001-11-23 2002-11-22 Anvendelse af glutamat, glutamatderivater eller metabolitter, glutamatanaloger eller blandinger deraf til fremstilling af en sammensætning til behandling af osteoporose
BR0214364-0A BR0214364A (pt) 2001-11-23 2002-11-22 Métodos para obter melhorada qualidade dos ossos de um vertebrado e para modular a qualidade dos ossos de um vertebrado, uso de glutamato, derivados de glutamato, ou metabólitos, análogos de glutamato ou misturas dos mesmos, e, método para inibir, prevenir ou aliviar a degradação da estrutura óssoa ou enfraquecimento óssea em um vertebrado
KR1020047007846A KR100961291B1 (ko) 2001-11-23 2002-11-22 골다공증 치료용 조성물의 제조에 사용되는 글루타메이트,글루타메이트 유도체 또는 대사산물, 글루타메이트 유사체또는 이들의 혼합물의 용도
CNB028245253A CN100531731C (zh) 2001-11-23 2002-11-22 谷氨酸盐、谷氨酸盐衍生物或代谢产物、谷氨酸盐类似物或其混合物在制备治疗骨质疏松症的组合物中的用途
MXPA04004904A MXPA04004904A (es) 2001-11-23 2002-11-22 Uso de glutamato, derivados o metabolitos de glutamato, analogos de glutamato o mezclas de los mismos para la preparacion de una composicion para el tratamiento de osteoporosis.
EP02791128.8A EP1446112B1 (en) 2001-11-23 2002-11-22 Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis
AU2002366111A AU2002366111B2 (en) 2001-11-23 2002-11-22 Use of glutamate, glutamate derivates or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis
CA2467676A CA2467676C (en) 2001-11-23 2002-11-22 Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis
ES02791128T ES2431085T3 (es) 2001-11-23 2002-11-22 Uso de glutamato, derivados o metabolitos de glutamato, análogos de glutamato o mezclas de los mismos para la fabricación de una composición para el tratamiento de osteoporosis
HK05101425.8A HK1071059A1 (en) 2001-11-23 2005-02-18 Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis
US14/101,234 US9233088B2 (en) 2001-11-23 2013-12-09 Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0103932 2001-11-23
SE0104385A SE520842C2 (sv) 2001-11-23 2001-12-21 Användning av glutamat, glutamatderivat, glutamatmetaboliter eller glutamatanaloger för att framställa en sammansättning för behandling av osteoporos
SE0201713A SE0201713D0 (sv) 2001-11-23 2002-06-06 New methods and use III

Publications (1)

Publication Number Publication Date
SE0201713D0 true SE0201713D0 (sv) 2002-06-06

Family

ID=27354772

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201713A SE0201713D0 (sv) 2001-11-23 2002-06-06 New methods and use III

Country Status (15)

Country Link
US (2) US8603981B2 (sv)
EP (1) EP1446112B1 (sv)
JP (1) JP4447913B2 (sv)
KR (1) KR100961291B1 (sv)
CN (1) CN100531731C (sv)
AU (1) AU2002366111B2 (sv)
BR (1) BR0214364A (sv)
CA (1) CA2467676C (sv)
DK (1) DK1446112T3 (sv)
ES (1) ES2431085T3 (sv)
HK (1) HK1071059A1 (sv)
MX (1) MXPA04004904A (sv)
PT (1) PT1446112E (sv)
SE (1) SE0201713D0 (sv)
WO (1) WO2003043626A1 (sv)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004237439B2 (en) 2003-05-07 2009-09-10 Osteologix A/S Treating cartilage/bone conditions with water-soluble strontium salts
BRPI0412118A (pt) * 2003-07-01 2006-08-15 Essentys Ab métodos para melhorar a absorção de aminoácidos, para reduzir a absorção da glicose plasmática, e para prevenir, inibir ou aliviar uma condição de elevado teor de glicose em um vertebrado, e, uso de akg, derivados ou metabólitos de akg, análogos de akg, ou misturas destes
SE0301947D0 (sv) * 2003-07-01 2003-07-01 Gramineer Internat Ab New method and uses
US7335686B2 (en) * 2003-10-20 2008-02-26 Council Of Scientific And Industrial Research Method and composition for treating osteoporosis
AU2005216596B2 (en) 2004-02-26 2011-03-24 Osteologix A/S Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
PL368573A1 (en) * 2004-06-17 2005-12-27 Sgp & Sons Ab Pharmaceutical compound influencing growth and mineralization processes in the axial and the appendicular skeleton as well as bone diseases of mature years among humans and animals as well as application of the pharmaceutical compound in the process of growth and mineralization of axial and appendicular skeleton and bone diseases of mature years among humans and animals
PL370937A1 (pl) * 2004-10-29 2006-05-02 Sgp & Sons Ab Preparat żywieniowy i/lub farmaceutyczny do stosowania w profilaktyce i leczeniu niedoborów wchłaniania mikroelementów z przewodu pokarmowego oraz zastosowanie preparatu farmaceutycznego jako czynnika stymulującego wchłanianie mikroelementów z przewodu pokarmowego do krwi
PL371081A1 (pl) * 2004-11-08 2006-05-15 Sgp & Sons Ab Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt
PL372183A1 (pl) * 2005-01-11 2006-07-24 Sgp & Sons Ab Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowego
US20110105617A1 (en) * 2005-01-11 2011-05-05 Sgp & Sons Ab Method for treatment of neoplastic diseases with alpha-keto glutarate and/or salts thereof
BRPI0618599A2 (pt) * 2005-11-15 2011-09-06 Entress Ab uso de um ácido alfa-cetoglutárico ou de um sal farmaceuticamente aceitável de ácido alfa-cetoglutárico
US20140037604A1 (en) * 2011-04-18 2014-02-06 Nestec S.A. Nutritional compositions comprising alpha-hydroxyisocaproic acid
CN103945858A (zh) * 2011-11-21 2014-07-23 埃默斯医疗股份有限公司 用于治疗糖尿病和相关病症的方法和组合物
CN102805857B (zh) * 2012-08-27 2014-07-02 北京紫萌同达科技有限公司 一种复方氨基酸(15)双肽(2)注射液的制备方法
CN105231038A (zh) * 2015-09-23 2016-01-13 华南农业大学 α-酮戊二酸在制备猪饲料添加剂方面的应用
JP2019527707A (ja) * 2016-08-01 2019-10-03 フィラメント バイオソリューションズ インコーポレーテッド 癌治療の副作用を治療及び予防する方法
CN110935005A (zh) * 2019-11-19 2020-03-31 宁波大学 一种丙谷二肽的新用途
CN111820330A (zh) * 2020-07-17 2020-10-27 禹城保立康生物饲料有限公司 一种提高哺乳仔猪发育的母猪饲料

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668295A (en) * 1985-04-25 1987-05-26 University Of Dayton Surgical cements
US5310768A (en) * 1987-10-29 1994-05-10 Ab Erik Vinnars Method for improving the glutamine content in skeletal muscle and composition therefore
JPH01216924A (ja) 1988-02-24 1989-08-30 Ajinomoto Co Inc 肝障害治療剤
US6451341B1 (en) * 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
JPH04164028A (ja) 1990-02-19 1992-06-09 Miwon Co Ltd グルタミン酸モノナトリウムを主成分とする疲労快復剤およびその使用方法
JP2702322B2 (ja) 1991-08-08 1998-01-21 フジックス株式会社 活性アミノ酸カルシウム、およびそれを含有する飲料、ならびにその製造方法
JP3551149B2 (ja) 1992-03-24 2004-08-04 味の素株式会社 易吸収性ミネラル含有組成物及びそれを含有する飲食品
US5646187A (en) * 1992-05-20 1997-07-08 Ab Erik Vinnars Use of alpha-ketoglutarate
JP2964290B2 (ja) 1992-08-25 1999-10-18 雪印乳業株式会社 ミネラル吸収促進剤
US5380934A (en) 1992-10-29 1995-01-10 Kyowa Hakko Kogyo Co., Ltd. Process for producing alanylgutamine
EP0605757B1 (en) 1992-11-25 2001-08-16 Ajinomoto Co., Inc. Compositions and goods containing minerals and poly-gamma-glutamic acid
US5849695A (en) * 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
SE9303691D0 (sv) 1993-11-09 1993-11-09 Gramineer Ab New beverage
CN1060336C (zh) * 1995-12-05 2001-01-10 孔彦平 一种防治钙质缺损的药物及其制备方法
US5817329A (en) * 1997-02-28 1998-10-06 Gardiner; Paul T. Nutritional supplement for increased muscle size and strength for body builders
NL1014380C2 (nl) 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.

Also Published As

Publication number Publication date
ES2431085T8 (es) 2014-01-03
CN1602190A (zh) 2005-03-30
AU2002366111B2 (en) 2007-06-28
WO2003043626A1 (en) 2003-05-30
JP2005518353A (ja) 2005-06-23
HK1071059A1 (en) 2005-07-08
PT1446112E (pt) 2013-10-21
MXPA04004904A (es) 2005-04-11
CA2467676C (en) 2011-07-12
US9233088B2 (en) 2016-01-12
ES2431085T3 (es) 2013-11-25
US8603981B2 (en) 2013-12-10
EP1446112A1 (en) 2004-08-18
CA2467676A1 (en) 2003-05-30
KR100961291B1 (ko) 2010-06-04
US20140194521A1 (en) 2014-07-10
BR0214364A (pt) 2004-10-26
KR20050044589A (ko) 2005-05-12
AU2002366111B8 (en) 2003-06-10
CN100531731C (zh) 2009-08-26
AU2002366111A1 (en) 2003-06-10
US20040259766A1 (en) 2004-12-23
JP4447913B2 (ja) 2010-04-07
EP1446112B1 (en) 2013-07-17
DK1446112T3 (da) 2013-10-07

Similar Documents

Publication Publication Date Title
SE0201713D0 (sv) New methods and use III
ATE322258T1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
NO20025590D0 (no) Fenylglycin-derivater
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
DE60327089D1 (de) Systeme zum verschieben und/oder zurückhalten von gewebe in den oberen atemwegen
BG106013A (en) New compounds and compositions as protease inhibitors
DK1638586T3 (da) Synergistisk sammensætning til behandling af diabetes mellitus
IL176110A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
GEP20084488B (en) Use of therapeutic agents for treating pain
CY1118179T1 (el) Φαρμακευτικη συνθεση
DE60036169D1 (de) Methoden zur Behandlung der Hautpigmentierung
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE495187T1 (de) Dalda-analoge und ihre verwendung
ATE301995T1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
SE0402762D0 (sv) Indazole sulphonamide derivatives
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
GB2352972A (en) Use of dexmedetomidine for icu sedation
SE0203303D0 (sv) Novel Compounds
ATE422892T1 (de) Verwendung von hyaluronsäure zur herstellung von zusammensetzungen zur behandlung rekurrenten aphthen in der mundhöhle
MXPA05007484A (es) Derivados de diarilmetilidina piperidina, preparacion y uso de los mismos.
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
SE0301947D0 (sv) New method and uses
BR0309747A (pt) Método para o tratamento de distúrbios vasculares mediados pelo fator de crescimento vascular endotelial
MXPA05013901A (es) Uso de acido alfa-cetoglutarico para tratamiento de desnutricion o condicion de glucosa alta en plasma.